Value of spectral parameters in the differential diagnosis of benign and malignant breast nodules in non-enhanced chest CT.

Abstract

Background: Dual-layer spectral computed tomography (DSCT) is capable of acquiring both conventional and spectral images during one routine scan, and is widely used for the quantitative and qualitative analyses of substances, differential diagnosis, and disease staging. However, limited research has been conducted on its performance in the differential diagnosis of benign and malignant breast nodules using non-enhanced scans. This study aimed to assess the diagnostic performance of multiple quantitative parameters derived from non-enhanced DSCT in differentiating benign from malignant breast nodules.

Methods: This retrospective cross-sectional study examined a total of 121 breast nodules from 114 patients (malignant group: n=68; benign group: n=53) identified during chest physical examination or routine admission for the treatment of breast diseases at The First Affiliated Hospital of Soochow University from March 2023 to December 2023. All the patients underwent DSCT scanning and pathological diagnosis. The DSCT quantitative parameters, including the effective atomic number (Zeff), computed tomography (CT) attenuation values at 40-70 keV, and the slope of the spectral Hounsfield unit curve (λHU), in non-enhanced images were measured. The λHU was calculated as follows: λHU = CT70 keV - CT40 keV/30 HU. Additionally, typical radiological features were analyzed. A DSCT parameter diagnostic model and a conventional CT diagnostic model were assessed using receiver operating characteristic (ROC) curves. The Delong test was used to assess and compare the diagnostic performance of each model.

Results: The DSCT parameters, including the Zeff (P<0.001), λHU (P<0.001), and CT attenuation values at 40 keV (P<0.001) and 50 keV (P=0.001), as well as the presence of the lobular sign (P<0.001) and spicule sign (P<0.001), exhibited statistically significant differences between the benign and malignant groups. The logistic regression analysis revealed that the Zeff [odds ratio (OR): 9.22; 95% confidence interval (CI): 2.11-40.35; P=0.003], λHU (OR: 0.64; 95% CI: 0.52-0.79; P<0.001), 40 keV CT attenuation value (OR: 8.69; 95% CI: 3.28-23.06; P<0.001), 50 keV CT attenuation value (OR: 0.01; 95% CI: 0.001-0.07; P<0.001), and lobular sign (OR: 3.95; 95% CI: 1.52-10.31; P=0.005) were independent predictors of malignancy. Compared to the benign group, the malignant group had a higher likelihood of presenting with the lobular sign and higher Zeff values but lower λHU values. The ROC curve indicated that the Zeff had the highest diagnostic efficacy [area under the curve (AUC) of the ROC =0.792, 95% CI: 0.71-0.87]. Further, the DSCT parameter diagnostic model had improved diagnostic efficacy with an AUC of 0.899 (95% CI: 0.84-0.96), which was higher than the AUC of the conventional CT diagnostic model (AUC =0.796, 95% CI: 0.72-0.87). The Delong test revealed a statistically significant difference between these two models (P=0.04).

Conclusions: DSCT parameters derived from non-enhanced DSCT images, such as the Zeff value and λHU, can be used to differentiate benign and malignant breast nodules, and the differential diagnosis efficacy of the DSCT parameters is higher than that of conventional CT parameters.